Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

被引：0

作者：

De Laurentiis, Michelino ^{[1
]}

Borstnar, Simona ^{[2
]}

Campone, Mario ^{[3
]}

Warner, Ellen ^{[4
]}

Bofill, Javier Salvador ^{[5
]}

Jacot, William ^{[6
]}

Dent, Susan ^{[7
,17
]}

Martin, Miguel ^{[8
]}

Ring, Alistair ^{[9
]}

Cottu, Paul ^{[10
]}

Lu, Janice ^{[11
]}

Ciruelos, Eva ^{[12
]}

Azim, Hamdy A. ^{[13
]}

Chatterjee, Sanjoy ^{[14
]}

Zhou, Katie ^{[15
]}

Wu, Jiwen ^{[15
]}

Menon-Singh, Lakshmi ^{[15
]}

Zamagni, Claudio ^{[16
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol Director, Div Breast Med Oncol, Naples, Italy

[2] Inst Oncol Ljubljana, Ljubljana, Slovenia

[3] Western Canc Inst, Nantes, France

[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[5] Virgen Rocio Univ Hosp, Biomed Inst, Seville, Spain

[6] Montpellier Canc Inst, Montpellier, France

[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[8] Univ Complutense, CIBERONC, GEICAM, Gregorio Maranon Gen Univ Hosp, Madrid, Spain

[9] Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England

[10] Curie Inst, Paris, France

[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Hosp 12 Octubre, Clara Campal Comprehens Canc Ctr, HM CIOCC, Madrid, Spain

[13] Cairo Univ, Fac Med, Cairo, Egypt

[14] Tata Med Ctr, Kolkata, India

[15] Novartis Pharmaceut, E Hanover, NJ USA

[16] Azienda Ospedaliero Univ Bologna, Bologna, Italy

[17] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2022年 / 191卷 / 01期

关键词：

D O I：

10.1007/s10549-021-06374-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：223 / 224

页数：2

共 50 条

[41] Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
Li, Huiping
Zhang, Qingyuan
Li, Wei
Wang, Shusen
Liao, Ning
Shen, Peng
Shao, Bin
Zhao, Wenhui
Sun, Wan
Yan, Ping
Wang, Diane
Li, Vince
Linn, Carlos
Shi, Haihong
O'Gorman, Melissa
Xu, Binghe
LANCET ONCOLOGY, 2017, 18 : S7 - S7
[42] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
Hortobagyi, Gabriel N.
Stemmer, Salomon M.
Burris, Howard A.
Yap, Yoon Sim
Sonke, Gabe S.
Paluch-Shimon, Shani
Campone, Mario
Petrakova, Katarina
Blackwell, Kimberly L.
Winer, Eric P.
Janni, Wolfgang
Verma, Sunil
Conte, Pier Franco
Arteaga, Carlos L.
Cameron, David A.
Xuan, Fengjuan
Miller, Michelle Kristine
Germa, Caroline
Hirawat, Samit
O'Shaughnessy, Joyce
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results.
Garin, A
Manikhas, A
Biakhov, M
Chezhin, M
Ivanchenko, T
Krejcy, K
Karaseva, V
Tjuyandin, S
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 51S - 51S
[44] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Abdel-Razeq, H.
Cottu, P. H.
Ring, A.
De laurentiis, M.
Lu, J.
Azim, H. A.
Zamagni, C.
Zhou, K.
Wu, J.
Menon, L.
Martin, M.
ANNALS OF ONCOLOGY, 2018, 29
[45] Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).
De laurentiis, Michelino
Borstnar, Simona
Campone, Mario
Warner, Ellen
Bofill, Javier Salvador
Jacot, William
Dent, Susan Faye
Martin, Miguel
Ring, Alistair E.
Cottu, Paul H.
Lu, Janice M.
Ciruelos, Eva
Azim, Hamdy A.
Chatterjee, Sanjoy
Zhou, Katie
Wu, Jiwen
Ankrah, Nii
Zamagni, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[46] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib 1 letrozole in hormone receptor-positive (HR1), HER2-negative (HER2-) advanced breast cancer (ABC)
Spazzapan, S.
Conte, P.
Simoncini, E.
Campone, M.
Miller, M.
Sonke, G.
ANNALS OF ONCOLOGY, 2017, 28
[47] Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women
Xu, Binghe
Zhang, Qingyuan
Li, Huiping
Sun, Wan
Li, Wei
Wang, Shusen
Liao, Ning
Shen, Peng
Shao, Bin
Zhao, Wenhui
Liu, Yuan
Li, Vincent
Linn, Carlos
Yan, Ping
Plotka, Anna
Jiang, John
Wang, Diane D.
CANCER RESEARCH, 2018, 78 (13)
[48] Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin plus /- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Sahai, Vaibhav
Griffith, Kent A.
Zhen, David Bing
Deming, Dustin A.
Shroff, Rachna T.
Hsieh, David
Mahalingam, Devalingam
Crysler, Oxana V.
Alistar, Angela Tatiana
Bajor, David L.
Enzler, Thomas
Zalupski, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Zamagni, C.
Campone, M.
Kudryavcev, I.
Brown-Glaberman, U.
Cottu, P. H.
Ring, A.
Lu, J.
Martin, M.
De laurentiis, M.
Zhou, K.
Wu, J.
Menon, L.
Azim, H. A.
ANNALS OF ONCOLOGY, 2018, 29
[50] Phase Ill trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer First efficacy results from the LEA study.
Martin, M.
Loibl, S.
von Minckwitz, G.
Morales, S.
Crespo, C.
Anton, A.
Guerrero, A.
Aktas, B.
Schoenegg, W.
Munoz, M.
Garcia-Saenz, J. A.
Gil, M.
Ramos, M.
Carrasco, E.
Liedtke, C.
Wachsmann, G.
Mehta, K.
De la Haba, J. R.
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →